TrialClinIQ | $150,000 | (Apr 29, 2026)
Lighthouse Pharmaceuticals | $12,000,000 | (Apr 29, 2026)
Windmill(US) | $12,000,000 | (Apr 29, 2026)
Certified by Founder
Lodge
Slate Medicines
start up
United States
- Raleigh, NC
- 25/02/2026
- Series A
- $130,000,000
Slate Medicines is a biotech company focused on advancing next generation therapeutics for migraine and other headache disorders. The Company’s lead program, SLTE-1009, is a potential best-in-class subcutaneous anti-PACAP for the prevention of migraine and other headache disorders. The company is backed by leading healthcare investors including RA Capital Management, Forbion, Foresite Capital, and an additional undisclosed biotech investor. For more information, please visit www.slatemedicines.com.
- Industry Biotechnology Research
- Website https://www.slatemedicines.com/
- LinkedIn https://www.linkedin.com/company/slate-medicines/
IC Realtime | $2,000,000 | (Apr 29, 2026)
Golden Child | $37,000,000 | (Apr 29, 2026)
Hypervision Surgical | $22,962,410 | (Apr 29, 2026)
dehaze | $3,746,192 | (Apr 29, 2026)
Clarasight | $11,500,000 | (Apr 29, 2026)
Liquid Instruments | $50,000,000 | (Apr 29, 2026)
TriFetch | $1,900,000 | (Apr 28, 2026)
Linexa | $2,342,840 | (Apr 28, 2026)
HrFlow.ai | $7,000,000 | (Apr 28, 2026)